Compounds > meglumine

meglumine and rb 101

meglumine has been researched along with rb 101 in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (88.89)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP1
Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O1
Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O1
Blommaert, AG; Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O1
Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F1
Besson, JM; Buritova, J; Fournié-Zaluski, MC; Honore, P; Roques, BP1
Elfvin, A; Fournié-Zaluski, MC; Hao, JX; Roques, BP; Wiesenfeld-Hallin, Z; Xu, XJ1
Coric, P; Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F; Smadja, C1
Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP1

Other Studies

9 other study(ies) available for meglumine and rb 101

ArticleYear
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    European journal of pharmacology, 1995, Jan-24, Volume: 273, Issue:1-2

    Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu

1995
Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    British journal of pharmacology, 1995, Volume: 114, Issue:5

    Topics: Analgesics; Animals; Behavior, Animal; Binding, Competitive; Body Temperature; Diprenorphine; Disulfides; Drug Combinations; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Mice; Morphine; Motor Activity; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Weight Loss

1995
Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    The Journal of pharmacology and experimental therapeutics, 1994, Volume: 270, Issue:1

    Topics: Adamantane; Analgesics; Animals; Benzodiazepinones; Dipeptides; Disulfides; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Nociceptors; Pain Measurement; Phenylalanine; Phenylurea Compounds; Prodrugs; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Regression Analysis; Tail

1994
Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    European journal of pharmacology, 1995, Nov-03, Volume: 286, Issue:1

    Topics: Analgesics; Animals; Benzodiazepinones; Disulfides; Drug Synergism; Drug Tolerance; Indoles; Male; Meglumine; Mice; Pain Measurement; Phenylalanine; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Time Factors

1995
Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
    British journal of pharmacology, 1996, Volume: 119, Issue:1

    Topics: Analgesics; Animals; Disulfides; Drug Combinations; Enkephalins; Indoles; Male; Meglumine; Methadone; Morphine; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome

1996
Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:1

    Topics: Analgesics; Animals; Benzodiazepinones; Devazepide; Disulfides; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Indoles; Male; Meglumine; Pain; Phenylalanine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Spinal Cord

1997
CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
    Neuropeptides, 1997, Volume: 31, Issue:3

    Topics: Analgesics; Animals; Decerebrate State; Disulfides; Dose-Response Relationship, Drug; Drug Synergism; Female; Hormone Antagonists; Indoles; Injections, Intravenous; Meglumine; Nociceptors; Opioid Peptides; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Reflex; Spinal Cord

1997
CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Psychopharmacology, 1997, Volume: 132, Issue:3

    Topics: Amygdala; Animals; Caudate Nucleus; Disulfides; Enkephalins; Enzyme Inhibitors; Hormone Antagonists; Indoles; Injections, Intraventricular; Limbic System; Male; Meglumine; Mice; Motor Activity; Neprilysin; Nucleus Accumbens; Phenylalanine; Rats; Rats, Wistar; Receptor, Cholecystokinin B; Receptors, Cholecystokinin

1997
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    British journal of pharmacology, 2001, Volume: 133, Issue:1

    Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss

2001